Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd Inc is positioned favorably within the clinical-stage biopharmaceutical sector, particularly with its development of antibodies aimed at infectious diseases, most notably COVID-19. The company has secured FDA approval for its Phase 3 program (REVOLUTION) for VYD2311, which could significantly expand its potential market by demonstrating superiority over existing mRNA vaccines. Additionally, the increasing global market for antibody treatments, projected to reach $3-4 billion by 2030, combined with the product candidates' innovative technologies, underpins a positive outlook for the company's financial prospects and market competitiveness.

Bears say

Invivyd Inc. is facing significant challenges, as evidenced by a misleading in silico modeling result that revealed a dramatic 200-fold decrease in the efficacy of its lead product candidate, ADG20, against the omicron variant during the STAMP trial. Compounding this issue, the overall market opportunity has diminished, with declining vaccination rates for COVID-19 and influenza, particularly among vulnerable populations such as the elderly and immunocompromised, who require effective solutions the most. Amidst concerns of vaccine hesitancy and a shrinking target demographic, the viability and commercial prospects of Invivyd's antibody-based therapies appear increasingly compromised.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.